India, Feb. 13 -- Servier, the independent French pharmaceutical group governed by a foundation, has announced the establishment of a global platform in India - 'GATINN' - to work with partners to develop, manufacture and export Single Pill Combinations (SPCs)for cardiometabolic and venous diseases.

The platform aims to improve adherence and enable better long-term outcomes for patients globally by simplifying treatment regimens through SPCs. The initiative reflects Servier's 2030 ambition to accelerate innovation and deliver patient-centric solutions, particularly in chronic conditions where treatment adherence remains a critical challenge.

Servier plans to invest approximately €15 million in 2026 in GATINN, working closely with ...